1 Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA, USA.
2 Division of Cardiovascular Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Cell Transplant. 2017 Nov;26(11):1755-1762. doi: 10.1177/0963689717732993.
In islet transplantation, in addition to immunologic and ischemic factors, the diabetic/hyperglycemic state of the recipient has been proposed, although not yet validated, as a possible cause of islet toxicity, contributing to islet loss during the engraftment period. Using a miniature swine model of islet transplantation, we have now assessed the effect of a persistent state of hyperglycemia on islet engraftment and subsequent function. An islet-kidney (IK) model previously described by our laboratory was utilized. Three experimental donor animals underwent total pancreatectomy and autologous islet transplantation underneath the renal capsule to prepare an IK at a load of ≤1,000 islet equivalents (IE)/kg donor weight, leading to a chronic diabetic state during the engraftment period (fasting blood glucose >250 mg/dL). Three control donor animals underwent partial pancreatectomy (sufficient to maintain normoglycemia during islet engraftment period) and IK preparation. As in vivo functional readout for islet engraftment, the IKs were transplanted across an immunologic minor or class I mismatch barrier into diabetic, nephrectomized recipients at an islet load of ∼4,500 IE/kg recipient weight. A 12-d course of cyclosporine was administered for tolerance induction. All experimental donors became diabetic and showed signs of end organ injury, while control donors maintained normoglycemia. All recipients of IK from both experimental and control donors achieved glycemic control over long-term follow-up, with reversal of diabetic nephropathy and with similar glucose tolerance tests. In this preclinical, large animal model, neither islet engraftment nor subsequent long-term islet function after transplantation appear to be affected by the diabetic state.
在胰岛移植中,除了免疫和缺血因素外,受体的糖尿病/高血糖状态也被认为是胰岛毒性的可能原因,尽管尚未得到证实,但这种毒性可能导致胰岛在植入期间丢失。我们使用小型猪胰岛移植模型,现在评估了持续高血糖状态对胰岛植入和随后功能的影响。我们实验室之前描述了一种胰岛-肾(IK)模型。三个实验供体动物接受了全胰切除术和自体胰岛移植到肾包膜下,以制备负荷≤1000 胰岛当量(IE)/kg 供体体重的 IK,导致植入期间慢性糖尿病状态(空腹血糖>250mg/dL)。三个对照供体动物接受了部分胰切除术(足以在胰岛植入期间维持正常血糖)和 IK 准备。作为胰岛植入的体内功能读出,IK 被移植到免疫性轻微或 I 类不匹配屏障内的糖尿病、肾切除受者体内,胰岛负荷约为 4500IE/kg 受者体重。给予环孢素 12 天疗程进行诱导耐受。所有实验供体动物均出现糖尿病并出现终末器官损伤迹象,而对照供体动物则保持正常血糖。所有来自实验和对照供体的 IK 受者在长期随访中均实现血糖控制,糖尿病肾病逆转,葡萄糖耐量试验相似。在这种临床前大型动物模型中,胰岛植入和移植后长期胰岛功能似乎不受糖尿病状态的影响。